1564P - Anaemia-related fatigue in patients with solid tumours: a multicenter, observational and prospective study (PACS study)

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Supportive Care
Presenter Pedro Gascon
Authors P. Gascon1, A. Casas2, J. Muñoz3, J. De Castro4, V. Alberola5, M. Cucala6, F. Barón7
  • 1Medical Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 2Medical Onology Department, Hospital Virgen del Rocío, Sevilla/ES
  • 3Medical Oncology Department, Hospital Dr. Peset, Valencia/ES
  • 4Medical Oncology Department, Hospital La Paz, Madrid/ES
  • 5Medical Oncology Department, Hospital Arnau de Vilanova, Valencia/ES
  • 6Medical Advisor, Vifor Pharma España, Barcelona/ES
  • 7Medical Oncology Department, Complejo hospitalario Universitario de Santiago de Compostela, Santiago de Compostela/ES



Quality of life in cancer patients is significantly reduced by anaemia and associated fatigue. Fatigue is one of the most common symptoms of cancer and cancer therapy. The aim of the present study was to evaluate fatigue in treatment-naive patients with solid tumours and after four months of cancer therapy using the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) questionnaire.


Multicenter, prospective and observational study that included newly diagnosed cancer patients. Patients completed the FACT-F questionnaire at baseline and after four months of cancer therapy. Anaemia status (haemoglobin <12 g/dL) was also recorded before and after cancer therapy. Hb levels were compared according to the presence or absence of severe fatigue (FACT-F < 30 points).


The study included 295 patients (153 females), mean age was 61.6 (±12.5). FACT-F score decreased by a mean of 2.4 points over the four months of cancer therapy (p< 0.001). The proportion of patients with severe fatigue was higher after cancer therapy: 23.6% vs 15.5% at baseline (p< 0.001). Most of the patients with severe fatigue were anaemic at baseline (69.8%) and at the four-month visit (71.2%). The proportion of patients with both anaemia and severe fatigue not receiving treatment was 26.2% at baseline and 24.3% after cancer therapy. According to type of cancer, the proportion of patients with severe fatigue at baseline was 21% in gastrointestinal cancer (GI), 18% in lung cancer and 4% in breast cancer. After therapy, these proportions were 24% in GI, 21% in lung cancer and 12% in breast cancer. There were differences in mean Hb levels according to the presence of severe fatigue at baseline (11.1 ± 1.6 vs 12.6 ± 1.7 g/dL in patients without severe fatigue, p< 0.001), as well as at the end of cancer therapy (11.1 ± 1.7 and 12.0 ± 1.4 g/dL)(p < 0.001).


Severe fatigue is highly correlated with anaemia before and after cancer therapy. The prevalence of fatigue increased with cancer therapy. Treatment of both cancer-related and treatment-related anaemia could reverse fatigue and have a positive effect on quality of life of cancer patients.


All authors have declared no conflicts of interest.